BDSX — Biodesix, Inc.

Biodesix, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Q4 revenue reached $28.8 million, with full-year revenue at $88.5 million, marking a 4,124% increase year-over-year.
• Lung Diagnostics Revenue: Q4 lung diagnostics revenue was $25.1 million, up 4,622% from the previous year, driven by a 23% increase in test volumes (18,000 tests).
• Gross Margin: Improved to 83% in Q4, up 400 basis points, and 81% for the full year, reflecting operational efficiencies.
• Adjusted EBITDA: Positive for the first time at $530,000 in Q4, with a full-year adjusted EBITDA loss of $17.5 million, an improvement of 21% over 2024.
• Cash Position: Ended Q4 with $19.0 million in unrestricted cash, bolstered by $14.7 million in at-the-market proceeds raised post-quarter.

2. Strategic Updates and Business Highlights

• Commercial Strategy: Focused on lung nodule management with a three-tiered approach targeting interventional pulmonologists, general pulmonologists, and primary care providers. Primary care accounted for 12% of total Nodify tests, growing 67% year-over-year.
• Partnerships: Announced collaborations with Thermo Fisher Scientific and Bio-Rad Laboratories to develop and validate tests, enhancing the company’s capabilities.
• Pipeline Development: Progress on multiple tests, including MRD tests and expansions of the VeriStrat test for various cancers, with an emphasis on AI-based digital diagnostics.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected annual revenue between $106 million and $112 million, representing a 23% growth over 2025.
• Sales Force Expansion: Plans to add approximately six sales representatives per quarter to enhance market penetration and drive growth.
• Operational Leverage: Anticipated continued improvements in adjusted EBITDA as the sales team gains experience and productivity.

4. Bad News, Challenges, or Points of Concern

• Seasonality and Weather Impact: Acknowledged potential revenue and volume declines in Q1 due to historical seasonality and recent weather disruptions, particularly in the Northeast.
• Claims Collections: Q4 included $1 million from claims older than one year, which may not recur in future quarters, potentially impacting revenue comparisons.
• Pipeline Commercialization: Emphasis on careful timing for new test launches to ensure reimbursement viability, delaying commercialization of some pipeline products.

5. Notable Q&A Insights

• Revenue Expectations: Analysts inquired about expected revenue declines in Q1, with management suggesting comparisons should exclude the one-time claim collections from Q4.
• Sales Rep Productivity: New sales representatives are expected to contribute significantly in 2026 as they gain experience; existing reps drove most of the growth in 2025.
• Pipeline Developments: Clarified that while there are exciting developments in the pipeline, no new tests are expected to launch in the next 12 months due to a focus on profitability and reimbursement.
• Stage Shift Evidence: Management noted positive feedback from physicians regarding earlier cancer detection through Nodify testing, with encouragement for independent publication of results to enhance credibility.

This summary encapsulates the key financial outcomes, strategic initiatives, future outlook, challenges, and insights from the Q&A session, providing a comprehensive overview of Biodesix, Inc.'s performance and direction.